ロード中...
Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers
OBJECTIVES: Data suggest that some licensed antiretroviral doses could be reduced. We assessed the safety, tolerability and pharmacokinetics of lopinavir/ritonavir at doses of 400/100, 200/150 and 200/50 mg twice daily in HIV-negative volunteers (http://clinicaltrials.gov/ct2/show/NCT00985543). METH...
保存先:
主要な著者: | , , , , , , , , , , , |
---|---|
フォーマット: | Artigo |
言語: | Inglês |
出版事項: |
2010
|
主題: | |
オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3594886/ https://ncbi.nlm.nih.gov/pubmed/21172791 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jac/dkq468 |
タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|